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Angiomyolipoma (AML) is a rare tumor mainly arising in the kidney. Here we report the case of a 55-year-old
woman with malignant epithelioid angiomyolipoma with p53 gene mutation. After 7 years from radical
nephrectomy of the left kidney, the patient developed multiple lung metastases that showed morphologic features
overlapping those of the previously lesion, which was misdiagnosed as renal cell carcinoma. Both renal and
pulmonary tumors were reevaluated by immunohistochemical assay, which were showed positive for HMB-45 and
p53 protein (95%), but negative for epithelial markers and S-100 protein. A correct diagnosis of malignant
epithelioid angiomyolipoma was made on the basis of those results. Meanwhile exon 8 mutation of p53 gene was
detected in the renal tumor by microdissection-PCR-SSCP and sequencing technique indicating that p53 gene
mutation may play an important role in malignant transformation. The patient was died of respiratory failure after
15 years’ follow-up. This is the second report of renal malignant angiomyolipoma with p53 gene mutation.
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Angiomyolipoma (AML) is now recognized as a clonal
mesenchymal neoplasm which stains strongly for
melanoma-associated markers (HMB-45). This tumor
most commonly arises in the kidney. Although typical
renal AML is a benign lesion, few cases of epithelioid
AML (EAML) develop malignant clinical courses. To
the best of our knowledge, only about 20 cases of renal
epithelioid AML with distant metastases have been
reported in the English-language literature [1].
The p53 gene is a tumor suppressor gene that plays an
important role in the regulation of cell growth, and the
expression of p53 protein has been closely correlated
with the presence of p53 gene mutation. Although a case
of renal EAML with a p53 missense mutation has been
reported [2], the pathogenesis and mechanisms of the
malignant transformation of AML remain unclear. In
the current study, we confirmed mutation of the p53* Correspondence: lijunfee@yahoo.com.cn
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reproduction in any medium, provided the orgene of malignant renal EAML with pulmonary metasta-
ses in a patient.Case presentation
A 55-year-old woman was hospitalized with left flank
pain for 3 months. Ultrasonography revealed a 7.5-cm
solid mass in the left kidney, and radical nephrectomy
was performed in May 1994. No evidence of tuberous
sclerosis complex or tumors in other locations were
found. Macroscopically, the tumor was reddish brown
and lobulated, had areas of necrosis and hemorrhaging
and a nonencapsulated mass measuring 7.5 cm × 7.0
cm. Microscopically, the tumor was composed of polyg-
onal epithelioid cells in a sheet pattern, which had huge,
pleomorphic and hyperchromatic nuclei with abundant
eosinophilic cytoplasm. Scattered tumor giant cells, mi-
totic figures and necrosis were frequently seen
(Figure 1A). The diagnosis of renal cell carcinoma
(RCC) was made without immunohistochemical examin-
ation. About 7 years after nephrectomy, CT showed a
mass of 8.0 cm in the lower pole (Figure 2A) and 1.5 cm
in the upper pole of the right lung (Figure 2B). Lobec-
tomy of the right lung was performed. The morphologic. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 (A) Microscopically, the renal tumor is composed of polygonal epithelioid cells with abundant eosinophilic cytoplasm,
pleomorphic nuclear and hyperchromatic nuclei (hematoxylin and eosin, original magnification 20×), and scattered tumor giant cells
and mitotic figures are frequently seen (lower right corner; hematoxylin and eosin, original magnification 40×). (B) The morphologic
features of lung relapses overlapped those of the renal lesion (hematoxylin and eosin, original magnification 20×). (C) and (D)
Immunohistochemically, the tumor cells of renal and pulmonary lesions show HMB-45 cytoplasmic reaction. (C) DAB, 20×. (D) DAB, 40×.
Figure 2 CT scan shows a mass of 8.0 cm in the lower pole (A) and a mass of 1.5 cm in the upper pole of the right lung (B).
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Primer sequence (5′-3′) Condition of
amplification
5 183 TACTCCCTGCCCCTCAACAAG 94°C, 1 minute; 55°C,
1 minute; 72°C,
ATCGCTATCTGAGCAGCGCTC 1 minute; 48 cycles
6 114 GGTCTGGCCCCTCCTCAGCAT 94°C, 1 minute; 63°C,
1 minute;72°C,
CTCAGGCGGCTCATAGGGCAC 1 minute; 50 cycles
7 111 GTTGGCTCTGACTGTACCACC 94°C, 1 minute; 55°C,
1 minute;72°C,
CCTGGAGTCTTCCAGTGTGAT 1 minute; 48 cycles
8 135 TGGTAATCTACTGGGACTGAA
TCGCTTAGTGCTCCCTGGGGG
94°C, 1 minute; 55°C,
1 minute; 72°C,
1 minute; 48 cycles
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renal lesion (Figure 1B). Both renal and pulmonary
tumors were reevaluated by immunohistochemical
assays. The results showed that the tumor cells of both
specimens were positive for vimentin, HMB-45
(Figures 1C and 1D) and p53 protein (approximately
95%) (Figure 3), but they were negative for cytokeratin
and S-100 protein. The corrected diagnosis of malignant
renal EAML with pulmonary metastases was made. No
chemotherapy or radiotherapy was administered post-
operatively. The patient died as a result of respiratory
failure due to multiple pulmonary metastases about 15
years after nephrectomy. Mutations of exons 5 through
8 were performed in the p53 gene by the polymerase
chain reaction single-strand conformation polymorph-
ism (PCR-SSCP) analysis and sequencing technique
according to previously described methods [2]. The
sequences of the primers and the condition of amplifica-
tion are listed in Table 1. The electrophoretic backward-
shifted bands were detected in exon 8 (Figure 4) of the
p53 gene in both renal and pulmonary epithelioid cells,
but no shift of electrophoretic mobility was found in
exons 5, 6 and 7 by PCR-SSCP analysis. Later, sequen-
cing confirmed exon 8 mutation of the p53 gene, which
was a missense mutation of T!G transversion at codon
281 (Figure 5) substituting serine for alanine.
Discussion
AML, one of the members of the PEComa family
(tumors showing perivascular epithelioid cell differenti-
ation), arises mainly in the kidney but may also occur in
other sites [3,4]. The typical AML is regarded as a be-
nign lesion, despite the presence of nuclear pleomorph-
ism and mitotic activity [2]. Although AML sometimes
shows extension into the vena cava or localization in theFigure 3 The tumor cells show strong immunoreactivity to p53
protein (3,3′-diaminobenzidine (DAB), original magnification
20×).regional lymph node, it is still considered to be a multi-
focal lesion rather than metastasis [5]. EAMLs are rare
variants with the capability of recurrence and metastasis.
Among them, approximately 50% of reported patients
developed metastases and 33% of patients died as a re-
sult of the disease [1,2,5-9].
There are no specific features of EAML in terms of
clinical manifestations and imaging modalities. The ap-
pearance of the lesions is similar to the findings in
patients with RCC [10]. Moreover, microscopically, the
presence of epithelioid cells can result in difficulty in dif-
ferentiating this tumor from RCC. In our case, the renal
tumor was misdiagnosed as RCC without immunohisto-
chemical results initially. In this situation, the immuno-
histochemical assay is significant in the differential
diagnosis. AML is characteristically positive for HMB-45,
a fact that is useful for discriminating carcinoma from
carcinoma-like AML. In the present case, by retrospective
analysis, the tumor cells of renal and pulmonary lesions
showed strong immunoreactivity to HMB-45, but neither
epithelial markers nor S-100 protein was immunopositive,
which allowed a definitive diagnosis of EAML.
The criteria for predicting malignancy in EAML are
not well-recognized because of the rarity of this entity.
These criteria include associated tuberous sclerosis com-
plex or concurrent AML, tumor size, extrarenal exten-
sion and/or renal vein involvement, carcinoma-like
growth pattern, cellular atypia, pleomorphic nuclei mi-
totic activity, and necrosis [1,11]. However, not all cases
with cytologic atypia correlate with poor prognosis.
Some investigators [7,8] have concluded that aggressive
behavior, such as cellular atypia, venous invasion and
local recurrence after incomplete surgical resection, should
not be interpreted as malignancy, and the diagnosis of ma-
lignancy can be made only on the basis of the presence of
Figure 4 PCR-SSCP analysis of exon 8 in the p53 gene. Bands
shift backward in both renal and pulmonary epithelioid cells.
N: normal renal parenchyma as a normal control, R: renal EAML,
P: pulmonary EAML.
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necrosis were palpable, and the diagnosis of malignant
EAML was confirmed by the pulmonary metastases.
The mechanism of the malignant transformation of
epithelioid AML is not evident. Although p53 mutation
has been described in one case report of renal EAML by
Kawaguchi et al. [2], no significant p53 mutation was
found in two other cases reported by Ma et al. [12] and
Sato et al. [13]. In the present case, diffuse nuclear p53
immunoreactivity and p53 gene abnormalities were iden-
tified in the renal and pulmonary lesions, which indicate
that p53 mutation may play an important role in the ma-
lignant nature of EAML. To the best of our knowledge,
this is the second published report of renal malignant
AML with p53 gene mutation.Figure 5 Direct DNA sequencing of exon 8 of the p53 gene. (A)
Normal renal parenchyma shows complementary sequence of
normal sequence that is promulgated in GenBank. (B) The malignant
epithelioid component of renal lesion shows T!G transversion at
codon 281.According to scattered reports, the disease-specific sur-
vival for malignant EAML varies greatly (3 months to 9
years) [1,2,5-11], and distant metastases may result in
death because effective chemotherapeutic methods of the
tumor have not yet been clearly established. In our case,
metastatic lesions were demonstrated and directly related
to the death of the patient 15 years after nephrectomy.
Because of the rarity of malignant EAML, the optimal
treatment is uncertain. Definitive diagnosis and radical
tumor surgical resection at an early stage could be im-
portant in the treatment of patients with renal EAML.
Adjuvant radiation and chemotherapy may have some
beneficial effect on overall survival, but the effects need
further investigation.
Conclusions
We report one rare case of a patient with renal malignant
EAML with pulmonary metastases and p53 gene muta-
tion. This entity is difficult to distinguish from RCC pre-
operatively. Accurate diagnosis depends on morphologic,
immunohistochemical examination and clinical follow-up.
p53 gene mutation might play a role in the malignant
transformation.
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